Flare changes after intravitreal injection of ocriplasmin in symptomatic vitreomacular traction syndrome

Purpose To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT). Study design An institutional review board-approved single-center not randomized prospective study. Methods Fif...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of ophthalmology Vol. 63; no. 3; pp. 255 - 261
Main Authors: Pirani, Vittorio, Pelliccioni, Paolo, Cesari, Claudia, Carrozzi, Giulia, Cavallero, Edoardo, Mariotti, Cesare
Format: Journal Article
Language:English
Published: Tokyo Springer Japan 01.05.2019
Springer Nature B.V
Subjects:
Anterior chamber
Chambers
Clinical Investigation
Diabetes
Edema
Injection
Iodine
Lasers
Measurement techniques
Medicine
Medicine & Public Health
Ophthalmology
Patients
Photons
Statistical analysis
Tomography
Traction
Women
Ocriplasmin
Vitreomacular traction syndrome
Laser flare photometry
Intravitreal injection
ISSN:0021-5155, 1613-2246, 1613-2246
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the changes in anterior chamber flare after a single intravitreal injection of ocriplasmin (125 μg), in patients with symptomatic vitreomacular traction syndrome (VMT). Study design An institutional review board-approved single-center not randomized prospective study. Methods Fifteen eyes of fifteen patients (9 women, 6 men) underwent intravitreal injection with ocriplasmin for symptomatic VMT (width of attachment ≤ 1500 μm). Anterior segment flare was measured with a laser flare meter (Kowa) before intravitreal injection and 1 day, 1 week, 1 month after injection. The changes in flare were analyzed; the resolution of VMT was evaluated with spectral-domain OCT. Results The mean anterior chamber flare was 10.5 ± 1.9 photons per millisecond (photons/ms) before the injection. After 1 day it increased to 13.6 ± 2.7 photons/ms (p = 0.027) and after 1 week to 14.4 ± 2.5 photons/ms (p = 0.005); after 1 month it decreased to 12.3 ± 2.3 photons/ms (p = 0.123). At 1 day and 1 week after injection, mean anterior chamber flare of fellow eyes was significantly lower than study eyes, while at 1 month this difference was not significant (12.3 ± 2.3 vs. 10.5 ± 1.8 photons/ms, p = 0.124, for study and fellow eyes). There was no statistically significant difference in the changes in flare between women and men or between phakic (N = 10) and pseudophakic (N = 5) eyes. No eye demonstrated intraretinal damage at any time-point. Also, 9 eyes showed resolution of VMT while 6 eyes demonstrated persistence of VMT. Conclusion Our study shows that intravitreal injection of ocriplasmin can be a safe and effective approach to treat symptomatic VMT syndrome in selected patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0021-5155
1613-2246
1613-2246
DOI:10.1007/s10384-019-00660-z